-
Je něco špatně v tomto záznamu ?
Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study
NCM. Visser, LJM. van der Putten, A. van Egerschot, KK. Van de Vijver, M. Santacana, P. Bronsert, M. Hirschfeld, E. Colas, A. Gil-Moreno, A. Garcia, G. Mancebo, F. Alameda, C. Krakstad, IL. Tangen, J. Huvila, S. Schrauwen, M. Koskas, F. Walker,...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, multicentrická studie
- MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- molekula buněčné adheze nervové L1 analýza biosyntéza MeSH
- nádorové biomarkery analýza MeSH
- nádory endometria patologie MeSH
- proteiny vázající RNA analýza biosyntéza MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- senzitivita a specificita MeSH
- stupeň nádoru metody MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
Discrimination between low- and high-grade endometrial carcinomas (ECs) is clinically relevant but can be challenging for pathologists, with moderate interobserver agreement. Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) is an oncofoetal protein that is associated with nonendometrioid endometrial carcinomas but has been limited studied in endometrioid carcinomas. The aim of this study is to investigate the diagnostic and prognostic value of IMP3 in the discrimination between low- and high-grade ECs and its added value to L1CAM. IMP3 and L1CAM expression was assessed in tumors from 378 patients treated for EC at 1 of 9 participating European Network for Individualised Treatment of Endometrial Cancer centers. IMP3 was expressed in 24.6% of the tumors. In general, IMP3 was more homogeneously expressed than L1CAM. IMP3 expression was significantly associated with advanced stage, nonendometrioid histology, grade 3 tumors, deep myometrial invasion, lymphovascular space invasion, distant recurrences, overall mortality, and disease-related mortality. Simultaneous absence of IMP3 and L1CAM expression showed the highest accuracy for identifying low-grade carcinomas (area under the curve 0.766), whereas simultaneous expression of IMP3 and L1CAM was strongly associated with high-grade carcinomas (odds ratio 19.7; 95% confidence interval 9.2-42.2). Even within endometrioid carcinomas, this combination remained superior to IMP3 and L1CAM alone (odds ratio 8.6; 95% confidence interval 3.4-21.9). In conclusion, IMP3 has good diagnostic value and together with L1CAM represents the optimal combination of diagnostic markers for discrimination between low- and high-grade ECs compared to IMP3 and L1CAM alone. Because of the homogenous expression of IMP3, this marker might be valuable in preoperative biopsies when compared to the more patchy L1CAM expression.
Comprehensive Cancer Centre Freiburg Medical Centre University of Freiburg 79106 Freiburg Germany
Department of Obstetrics and Gynaecology Haukeland University Hospital 5021 Bergen Norway
Department of Obstetrics and Gynaecology Hospital del Mar 8003 Barcelona Spain
Department of Obstetrics and Gynaecology University Medical Centre Freiburg 79106 Freiburg Germany
Department of Pathology Canisius Wilhelmina Hospital 6500 GS Nijmegen the Netherlands
Department of Pathology Ghent University Hospital 9000 Ghent Belgium
Department of Pathology Hospital del Mar 8003 Barcelona Spain
Department of Pathology Radboud University Medical Centre 6500HB Nijmegen the Netherlands
Department of Pathology University of Turku 20500 Turku Finland
Faculty of Medicine University of Freiburg 79085 Freiburg Germany
German Cancer Consortium 69120 Heidelberg Germany
Gynecological Department Vall Hebron University Hospital CIBERONC 8035 Barcelona Spain
Institute for Surgical Pathology Medical Centre University of Freiburg 79085 Freiburg Germany
Obstetrics and Gynaecology Department Bichat Claude Bernard Hospital 75877 Paris France
Pathology Department Bichat Claude Bernard Hospital 75877 Paris France
Pathology Department Vall Hebron University Hospital 8035 Barcelona Spain
Radboud Institute for Molecular Life Sciences 6500HB Nijmegen the Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023851
- 003
- CZ-PrNML
- 005
- 20201214131429.0
- 007
- ta
- 008
- 201125s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.humpath.2019.04.014 $2 doi
- 035 __
- $a (PubMed)31054899
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Visser, Nicole C M $u Department of Pathology, Radboud University Medical Centre, 6500HB, Nijmegen, the Netherlands; Radboud Institute for Molecular Life Sciences, 6500HB, Nijmegen, the Netherlands. Electronic address: Nicole.Visser@radboudumc.nl.
- 245 10
- $a Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study / $c NCM. Visser, LJM. van der Putten, A. van Egerschot, KK. Van de Vijver, M. Santacana, P. Bronsert, M. Hirschfeld, E. Colas, A. Gil-Moreno, A. Garcia, G. Mancebo, F. Alameda, C. Krakstad, IL. Tangen, J. Huvila, S. Schrauwen, M. Koskas, F. Walker, V. Weinberger, L. Minar, J. Hausnerova, MPLM. Snijders, S. van den Berg-van Erp, X. Matias-Guiu, J. Trovik, F. Amant, LFAG. Massuger, J. Bulten, JMA. Pijnenborg,
- 520 9_
- $a Discrimination between low- and high-grade endometrial carcinomas (ECs) is clinically relevant but can be challenging for pathologists, with moderate interobserver agreement. Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) is an oncofoetal protein that is associated with nonendometrioid endometrial carcinomas but has been limited studied in endometrioid carcinomas. The aim of this study is to investigate the diagnostic and prognostic value of IMP3 in the discrimination between low- and high-grade ECs and its added value to L1CAM. IMP3 and L1CAM expression was assessed in tumors from 378 patients treated for EC at 1 of 9 participating European Network for Individualised Treatment of Endometrial Cancer centers. IMP3 was expressed in 24.6% of the tumors. In general, IMP3 was more homogeneously expressed than L1CAM. IMP3 expression was significantly associated with advanced stage, nonendometrioid histology, grade 3 tumors, deep myometrial invasion, lymphovascular space invasion, distant recurrences, overall mortality, and disease-related mortality. Simultaneous absence of IMP3 and L1CAM expression showed the highest accuracy for identifying low-grade carcinomas (area under the curve 0.766), whereas simultaneous expression of IMP3 and L1CAM was strongly associated with high-grade carcinomas (odds ratio 19.7; 95% confidence interval 9.2-42.2). Even within endometrioid carcinomas, this combination remained superior to IMP3 and L1CAM alone (odds ratio 8.6; 95% confidence interval 3.4-21.9). In conclusion, IMP3 has good diagnostic value and together with L1CAM represents the optimal combination of diagnostic markers for discrimination between low- and high-grade ECs compared to IMP3 and L1CAM alone. Because of the homogenous expression of IMP3, this marker might be valuable in preoperative biopsies when compared to the more patchy L1CAM expression.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a nádorové biomarkery $x analýza $7 D014408
- 650 _2
- $a nádory endometria $x patologie $7 D016889
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a stupeň nádoru $x metody $7 D060787
- 650 _2
- $a molekula buněčné adheze nervové L1 $x analýza $x biosyntéza $7 D039842
- 650 _2
- $a proteiny vázající RNA $x analýza $x biosyntéza $7 D016601
- 650 _2
- $a senzitivita a specificita $7 D012680
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a van der Putten, Louis J M $u Department of Obstetrics and Gynaecology, Radboud University Medical Centre, 6500HB, Nijmegen, the Netherlands.
- 700 1_
- $a van Egerschot, Alex $u Department of Pathology, Radboud University Medical Centre, 6500HB, Nijmegen, the Netherlands.
- 700 1_
- $a Van de Vijver, Koen K $u Department of Pathology, Ghent University Hospital, 9000, Ghent, Belgium.
- 700 1_
- $a Santacana, Maria $u Department of Pathology and Molecular Genetics and Oncological Pathology Group, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLLEIDA, CIBERONC, 25198, Lleida, Spain.
- 700 1_
- $a Bronsert, Peter $u Institute for Surgical Pathology, Medical Centre-University of Freiburg, 79085, Freiburg, Germany; Comprehensive Cancer Centre Freiburg, Medical Centre-University of Freiburg, 79106, Freiburg, Germany; Faculty of Medicine, University of Freiburg, 79085, Freiburg, Germany.
- 700 1_
- $a Hirschfeld, Marc $u Department of Obstetrics and Gynaecology, University Medical Centre Freiburg, 79106, Freiburg, Germany; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), 69120, Heidelberg, Germany.
- 700 1_
- $a Colas, Eva $u Biomedical Research Group in Gynaecology, Vall Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, CIBERONC, 08193, Barcelona, Spain.
- 700 1_
- $a Gil-Moreno, Antonio $u Biomedical Research Group in Gynaecology, Vall Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, CIBERONC, 08193, Barcelona, Spain; Gynecological Department, Vall Hebron University Hospital, CIBERONC, 8035, Barcelona, Spain.
- 700 1_
- $a Garcia, Angel $u Pathology Department, Vall Hebron University Hospital, 8035, Barcelona, Spain.
- 700 1_
- $a Mancebo, Gemma $u Department of Obstetrics and Gynaecology, Hospital del Mar, 8003, Barcelona, Spain.
- 700 1_
- $a Alameda, Francesc $u Department of Pathology, Hospital del Mar, 8003, Barcelona, Spain.
- 700 1_
- $a Krakstad, Camilla $u Department of Obstetrics and Gynaecology, Haukeland University Hospital, 5021, Bergen, Norway; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5021, Bergen, Norway.
- 700 1_
- $a Tangen, Ingvild L $u Department of Obstetrics and Gynaecology, Haukeland University Hospital, 5021, Bergen, Norway; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5021, Bergen, Norway.
- 700 1_
- $a Huvila, Jutta $u Department of Pathology, University of Turku, 20500, Turku, Finland.
- 700 1_
- $a Schrauwen, Stefanie $u Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, University Hospital Gasthuisberg, 3000, Leuven, Belgium.
- 700 1_
- $a Koskas, Martin $u Obstetrics and Gynaecology Department, Bichat-Claude Bernard Hospital, 75877, Paris, France.
- 700 1_
- $a Walker, Francine $u Pathology Department, Bichat-Claude Bernard Hospital, 75877, Paris, France.
- 700 1_
- $a Weinberger, Vit $u Department of Obstetrics and Gynaecology, University Hospital Brno, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic.
- 700 1_
- $a Minar, Lubos $u Department of Obstetrics and Gynaecology, University Hospital Brno, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic.
- 700 1_
- $a Hausnerova, Jitka $u Department of Pathology, University Hospital Brno, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic.
- 700 1_
- $a Snijders, Marc P L M $u Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital, 6500, GS, Nijmegen, the Netherlands.
- 700 1_
- $a van den Berg-van Erp, Saskia $u Department of Pathology, Canisius-Wilhelmina Hospital, 6500, GS, Nijmegen, the Netherlands.
- 700 1_
- $a Matias-Guiu, Xavier $u Department of Pathology and Molecular Genetics and Oncological Pathology Group, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLLEIDA, CIBERONC, 25198, Lleida, Spain.
- 700 1_
- $a Trovik, Jone $u Department of Obstetrics and Gynaecology, Haukeland University Hospital, 5021, Bergen, Norway; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5021, Bergen, Norway.
- 700 1_
- $a Amant, Frédéric $u Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, University Hospital Gasthuisberg, 3000, Leuven, Belgium; Department of Gynaecologic Oncology, Centre Gynaecologic Oncology Amsterdam (CGOA), Netherlands Cancer Institute and Amsterdam University Medical Centres, Academic Medical Centre, 1105, AZ, Amsterdam, the Netherlands.
- 700 1_
- $a Massuger, Leon F A G $u Department of Obstetrics and Gynaecology, Radboud University Medical Centre, 6500HB, Nijmegen, the Netherlands.
- 700 1_
- $a Bulten, Johan $u Department of Pathology, Radboud University Medical Centre, 6500HB, Nijmegen, the Netherlands.
- 700 1_
- $a Pijnenborg, Johanna M A $u Department of Obstetrics and Gynaecology, Radboud University Medical Centre, 6500HB, Nijmegen, the Netherlands.
- 773 0_
- $w MED00002080 $t Human pathology $x 1532-8392 $g Roč. 89, č. - (2019), s. 90-98
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31054899 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214131427 $b ABA008
- 999 __
- $a ok $b bmc $g 1596170 $s 1114527
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 89 $c - $d 90-98 $e 20190503 $i 1532-8392 $m Human pathology $n Hum Pathol $x MED00002080
- LZP __
- $a Pubmed-20201125
